Epcoritamab
Epcoritamab is a bispecific T-cell engaging antibody used to treat certain types of relapsed or refractory non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). It works by binding simultaneously to CD20 on cancer cells and CD3 on T-cells, redirecting the immune system to recognize and destroy malignant B-cells.
Epcoritamab is a targeted immunotherapy that bridges T-cells with cancer cells to treat relapsed or refractory B-cell lymphomas.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01FX27
- RxNorm
- 2637392
- Generic
- Epcoritamab
- Class
- atc-l01
- Brands
- Epkinly
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring and uterine activity monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding or avoid
it is unknown whether epcoritamab is excreted in human milk
monitor infant for adverse effects
pediatric_age
children under 18not recommended
epcoritamab is not approved for use in pediatric patients
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 and olderno specific dose adjustment required
use with caution due to increased susceptibility to adverse reactions
close monitoring for adverse reactions and cytokine release syndrome
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno dose adjustment required
no clinically significant effect on pharmacokinetics expected
standard monitoring
renal_impairment
severeuse with caution
limited data available in severe renal impairment
close monitoring for adverse reactions
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno dose adjustment required
not metabolized by hepatic CYP enzymes
standard monitoring
hepatic_impairment
moderate to severeuse with caution
limited data available in moderate to severe hepatic impairment
close monitoring for adverse reactions
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Immunotherapy drug class classification
FDA approval year
FDA approval for relapsed or refractory diffuse large B-cell lymphoma
Common uses
Primary therapeutic indication
Mechanism of action
Pharmacodynamic mechanism
Epcoritamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have received two or more prior lines of systemic therapy.
Epcoritamab is a bispecific antibody that simultaneously binds to CD20 on the surface of B-cells (including cancer cells) and CD3 on the surface of T-cells. This dual binding bridges cancer cells with immune cells, activating T-cells to release cytotoxic substances that destroy the malignant B-cells.
Epcoritamab is administered via subcutaneous injection and carries risks of serious side effects including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections. Patients require monitoring during and after administration. It targets both malignant and healthy B-cells, potentially causing B-cell depletion.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy